12:00 AM
Jan 02, 2012
 |  BC Week In Review  |  Company News  |  Other News

Paion cardiovascular, neurology news

Paion also said it has not identified a partner for pain product M6G. The biotech noted its chances of partnering it are "considerably lower than expected in the past" and will result in an impairment charge of €6.1 million ($7.9 million) recorded in its 2011 financial earnings. The morphine-6-glucoronide (M6G) metabolite of morphine completed two Phase III trials for postoperative pain.

Paion said CFO Bernhard Hofer will step down from the management board at the end of...

Read the full 379 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >